MEI Pharma Inc. has reported its third-quarter results for the fiscal year 2025, ending March 31, 2025. The company disclosed a cash position of $20.5 million with no outstanding debt. In light of ongoing strategic evaluations, MEI Pharma is exploring potential alternatives to enhance asset value for stockholders. These options include out-licensing existing programs and pursuing merger and acquisition opportunities. Oppenheimer & Co., Inc. is advising the company throughout this process. MEI Pharma continues to implement cash preservation measures, including a staged reduction-in-force, as it adapts its operational and strategic direction. As of now, there are no guarantees that the exploration of strategic alternatives will result in agreements or transactions, nor any assurance of their success or terms. The company has indicated it will not disclose updates on this process until it is completed or deemed necessary.